カテゴリ： GlobalData, スペイン, 企業調査

Grifols SA (GRF)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Grifols SA (GRF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10099
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：88
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スペイン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. The company offers its products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA (GRF) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10
Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Grifols SA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Partnerships 14
Araclon Biotech Enters into Agreement with TFS International 14
Grifols and GigaGen Enter into Research Agreement 15
Grifols Enters into Agreement with MassBiologics 16
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17
Licensing Agreements 18
Grifols Enters Into Licensing Agreement With Aradigm 18
ThromboGenics Enters into Licensing Agreement with Grifols 20
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21
Equity Offering 22
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22
TiGenix Completes Private Placement Of Shares For US$16.2 Million 23
Debt Offering 24
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 25
Acquisition 26
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27
Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28
Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30
Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 32
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 33
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 34
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35
Grifols Acquires 51% Stake In Araclon Biotech 36
Grifols SA – Key Competitors 37
Grifols SA – Key Employees 38
Grifols SA – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 44
Strategy And Business Planning 44
Sep 24, 2018: Grifols Announces the Opening of Biotest Pharmaceuticals Corporation’s Newest Plasma Donor Center in Bowling Green, Ohio 44
Financial Announcements 45
Jul 27, 2018: Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7% 45
May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 50
Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 53
Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 57
May 03, 2017: Bioscience Division sales increase 15% to drive Grifols’ revenue growth by 11% to Euros 1,062 million 63
Feb 28, 2017: Grifols’ revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 67
Corporate Communications 75
Apr 17, 2018: Grifols donates over 25 million international units of blood clotting factor in 2017 75
Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program 76
Legal and Regulatory 77
Jun 08, 2018: Grifols’ Building Receives LEED Certification 77
Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on ‘688 Patent 78
Government and Public Interest 79
Oct 08, 2018: Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support 79
Sep 22, 2017: An ISCIII researcher awarded for her work on Alpha-1 Antitrypsin Deficiency (DAAT) 80
Jun 24, 2017: Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation’s John W. Walsh Research Fund 81
Product News 82
Jun 22, 2017: Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples 82
Other Significant Developments 83
Jul 05, 2018: Grifols, the newest angel of elBullifoundation 83
Jun 28, 2018: Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2017 84
May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 85
May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88

List of Tables
Grifols SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Deals By Therapy Area, 2012 to YTD 2018 9
Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10
Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Araclon Biotech Enters into Agreement with TFS International 14
Grifols and GigaGen Enter into Research Agreement 15
Grifols Enters into Agreement with MassBiologics 16
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17
Grifols Enters Into Licensing Agreement With Aradigm 18
ThromboGenics Enters into Licensing Agreement with Grifols 20
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22
TiGenix Completes Private Placement Of Shares For US$16.2 Million 23
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 25
Grifols Shared Services North America Acquires Biotest for USD286 Million 26
Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27
Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28
Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30
Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 32
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 33
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 34
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35
Grifols Acquires 51% Stake In Araclon Biotech 36
Grifols SA, Key Competitors 37
Grifols SA, Key Employees 38
Grifols SA, Other Locations 39
Grifols SA, Subsidiaries 39

List of Figures
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Grifols SA (GRF)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • ASKA Pharmaceutical Co Ltd (4514)：製薬・医療：M&Aディール及び事業提携情報
    Summary ASKA Pharmaceutical Co Ltd (ASKA) is a pharmaceutical company that offers quasi-drugs, foods, medical devices and veterinary medicines. The company imports and export pharmaceuticals and medical devices. Its activities comprise production, drug information, and research and development servi …
  • Corby Spirit and Wine Limited：企業の戦略・SWOT・財務分析
    Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report Summary Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Senior Housing Properties Trust：企業のM&A・事業提携・投資動向
    Senior Housing Properties Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Senior Housing Properties Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Blue Moon Zinc Corp.：企業の戦略・SWOT・財務情報
    Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report Summary Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Central Rand Gold Ltd：企業の戦略・SWOT・財務情報
    Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bio-Rad Laboratories Inc (BIO)：企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • PhaseBio Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary PhaseBio Pharmaceuticals Inc (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company offers ELP biopolymer technology, which includes PE0139 and PB1023 pipeline products. PhaseBio …
  • Benihana Inc.：企業の戦略・SWOT・財務情報
    Benihana Inc. - Strategy, SWOT and Corporate Finance Report Summary Benihana Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Numab Innovation AG：製薬・医療：M&Aディール及び事業提携情報
    Summary Numab Innovation AG (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company’s pipeline products include ND007, ND009, ND016, ND017, ND023, ND026, and ND021. Its ND007 is a bispecific antibody fragment which is being evaluated for the treatment of autoim …
  • Brady Corporation：企業の戦略・SWOT・財務分析
    Brady Corporation - Strategy, SWOT and Corporate Finance Report Summary Brady Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Qioptiq Group：企業の戦略的SWOT分析
    Qioptiq Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Tohoku Electric Power Co Inc：発電所・企業SWOT分析
    Tohoku Electric Power Co Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Volkswagen AG (VOW3)-エネルギー分野：企業M&A・提携分析
    Summary Volkswagen AG (Volkswagen) is an automobile company involved in the design, development, production and sales of a wide range of vehicles and engines. It commercializes both passenger and commercial vehicles, including low consumption small cars and luxury class vehicles. The company sells i …
  • Wesfarmers Limited：戦略・SWOT・企業財務分析
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Romelectro S.A.：企業の戦略的SWOT分析
    Romelectro S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Fast Track Diagnostics Ltd.：企業の製品パイプライン分析2018
    Summary Fast Track Diagnostics Ltd. (Fast Track) is engaged in designing, manufacturing and supplying of infectious disease detection kits. It offers Real Time PCR multiplexing kits in human and veterinary line platforms. The company’s products comprises of FTD Human Papillomavirus (HPV) high risk k …
  • Sunstar Holding AG：企業の戦略・SWOT・財務情報
    Sunstar Holding AG - Strategy, SWOT and Corporate Finance Report Summary Sunstar Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Dana Petroleum Ltd：企業の戦略的SWOT分析
    Dana Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Novo Nordisk A/S：企業のM&A・事業提携・投資動向
    Novo Nordisk A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Novo Nordisk A/S Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Jadason Enterprises Limited (J03)：企業の財務・戦略的SWOT分析
    Jadason Enterprises Limited (J03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆